Annals of Surgical Oncology

, Volume 21, Issue 8, pp 2506–2511 | Cite as

Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer

  • Adrienne B. Gropper
  • Katherina Zabicki Calvillo
  • Laura Dominici
  • Susan Troyan
  • Esther Rhei
  • Katherine E. Economy
  • Nadine M. Tung
  • Lidia Schapira
  • Jane L. Meisel
  • Ann H. Partridge
  • Erica L. Mayer
Breast Oncology



Sentinel lymph node biopsy (SNB) in pregnant women with breast cancer is uncommonly pursued given concern for fetal harm. This study evaluated efficacy and safety outcomes in pregnant breast cancer patients undergoing SNB.


Patients who underwent SNB while pregnant were identified from a retrospective parent cohort of women diagnosed with breast cancer during pregnancy. Chart review was performed to tabulate patient/tumor characteristics, method/outcome of SNB, and short-term maternal/fetal outcomes.


Within a cohort of 81, 47 clinically node-negative patients had surgery while pregnant: 25 (53.2 %) SNB, 20 (42.6 %) upfront axillary lymph node dissection, and 2 (4.3 %) no lymph node surgery. Of SNB patients, 8, 9, and 8 had SNB in the first, second, and third trimesters, respectively. 99 m-Technetium (99-Tc) alone was used in 16 patients, methylene blue dye alone in 7 patients, and 2 patients had unknown mapping method. Mapping was successful in all patients. There were no SNB-associated complications. At a median of 2.5 years from diagnosis, there was one locoregional recurrence, one new primary contralateral tumor, three distant recurrences, and one breast cancer death. Among patients who underwent SNB, there were 25 liveborn infants, of whom 24 were healthy, and 1 had cleft palate (in the setting of other maternal risk factors).


SNB in pregnant breast cancer patients appears to be safe and accurate using either methylene blue or 99-Tc. This is one of the largest reported experiences of SNB during pregnancy; however, numbers remain limited. SNB rates in this cohort were lower than in non-pregnant breast cancer patients.


  1. 1.
    Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008;100:462–474.PubMedCrossRefGoogle Scholar
  2. 2.
    Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–933.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595–600.PubMedCrossRefGoogle Scholar
  4. 4.
    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–575.PubMedCrossRefGoogle Scholar
  5. 5.
    Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553.PubMedCrossRefGoogle Scholar
  6. 6.
    Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer. J Surg Oncol. 2011;103:337–340.PubMedCrossRefGoogle Scholar
  7. 7.
    Rodriguez AO, Chew H, Cress R, Xing G, McElvy S, Danielsen B, Smith L. Evidence of poorer survival in pregnancy-associated breast cancer. Obstet Gynecol. 2008;112:71–78.PubMedCrossRefGoogle Scholar
  8. 8.
    Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 2006;106:237–246.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542–2551.Google Scholar
  10. 10.
    Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–7720.PubMedCrossRefGoogle Scholar
  11. 11.
    Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CE, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16:1143–1147.PubMedCrossRefGoogle Scholar
  13. 13.
    Dubernard G, Garbay JR, Rouzier R, Delaloge S. Safety of sentinel node biopsy in pregnant patients. Ann Oncol. 2005;16:987;987–988.Google Scholar
  14. 14.
    Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003;138:91–98; discussion 99.Google Scholar
  15. 15.
    Meisel JL, Economy KE, Calvillo KZ, et al. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus. 2013;2:297.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Mondi MM, Cuenca RE, Ollila DW, Stewart JH 4th, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol. 2007;14:218–221.PubMedCrossRefGoogle Scholar
  17. 17.
    Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14:250–254.PubMedCrossRefGoogle Scholar
  18. 18.
    Andtbacka RH, Donaldson MR, Bowles TL, et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013;20:689–696.PubMedCrossRefGoogle Scholar
  19. 19.
    Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99 mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47:1202–1208.PubMedGoogle Scholar
  20. 20.
    Gentilini O, Cremonesi M, Trifiro G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348–1351.PubMedCrossRefGoogle Scholar
  21. 21.
    Keleher A, Wendt R 3rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10:492–495.PubMedCrossRefGoogle Scholar
  22. 22.
    Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK, et al. Allergic reactions to isosulfan blue during sentinel node biopsy: a common event. Surgery. 2001;130:439–442.PubMedCrossRefGoogle Scholar
  23. 23.
    Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182:393–398.PubMedCrossRefGoogle Scholar
  24. 24.
    Masannat YA, Hanby A, Horgan K, Hardie LJ. DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res. 2009;154:234–238.PubMedCrossRefGoogle Scholar
  25. 25.
    Pruthi S, Haakenson C, Brost BC, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011;201:70–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Cody HS 3rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13–19.PubMedCrossRefGoogle Scholar
  27. 27.
    Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012;36:2239–2251.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Keleher AJ, Theriault RL, Gwyn KM, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002;194:54–64.PubMedCrossRefGoogle Scholar
  29. 29.
    Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31:2532–2539.PubMedCrossRefGoogle Scholar
  30. 30.
    Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? J Clin Oncol. 2013;31:2521–2522.PubMedCrossRefGoogle Scholar
  31. 31.
    Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98:1055–1060.PubMedCrossRefGoogle Scholar
  32. 32.
    Rutgers EJ, Donker M, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial [abstract no. LBA1001]. J Clin Oncol. 2013;31 Suppl.Google Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Adrienne B. Gropper
    • 1
  • Katherina Zabicki Calvillo
    • 1
  • Laura Dominici
    • 1
  • Susan Troyan
    • 1
  • Esther Rhei
    • 1
  • Katherine E. Economy
    • 2
  • Nadine M. Tung
    • 3
  • Lidia Schapira
    • 4
  • Jane L. Meisel
    • 1
  • Ann H. Partridge
    • 1
  • Erica L. Mayer
    • 1
  1. 1.Dana-Farber/Brigham and Women’s Cancer CenterBostonUSA
  2. 2.Brigham and Women’s HospitalBostonUSA
  3. 3.Beth Israel Deaconess Medical CenterBostonUSA
  4. 4.Massachusetts General HospitalBostonUSA

Personalised recommendations